Transfusion-related acute lung injury: transfusion, platelets and biological response modifiers

Expert Review of Hematology

Volumn 9, Issue 5, 2016, Pages 497-508

  Tariket, Sofiane ^a   Sut, Caroline ^a   Hamzeh Cognasse, Hind ^a   Laradi, Sandrine ^a,b   Pozzetto, Bruno ^a   Garraud, Olivier ^a,c   Cognasse, Fabrice ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

biological response modifiers; inflammation; Platelet; TRALI; transfusion

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CD40 LIGAND; HLA ANTIGEN; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; PROSTAGLANDIN E2; RANTES; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE CONCENTRATE; THROMBOXANE A2; ANTIBODY; ANTIGEN; IMMUNOLOGIC FACTOR;

ACUTE LUNG INJURY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CELL FUNCTION; CELL INTERACTION; CELL POPULATION; CELL SURFACE; CELLULAR SECRETION; ERYTHROCYTE CONCENTRATE; EXPERIMENTAL MODEL; HUMAN; LEUKOCYTE; LUNG BLOOD VESSEL; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SURFACE PROPERTY; THROMBOCYTE; THROMBOCYTE FUNCTION; TRANSFUSION RELATED ACUTE LUNG INJURY; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; IMMUNOLOGY; METABOLISM; MORTALITY;

ACUTE LUNG INJURY; ANIMALS; ANTIBODIES; ANTIGENS; BLOOD PLATELETS; BLOOD TRANSFUSION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL;

EID: 84959045213     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2016.1152177     Document Type: Review

References (152)

1. R.Dasararaju, M.B.Marques Adverse effects of transfusion. Cancer Control: J Moffitt Cancer Center. 2015;22(1):16–25.
2. Y.Lin, C.L.Saw, B.Hannach, et al. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion. 2012;52(3):567–574.
3. A.P.Vlaar, N.P.Juffermans. Transfusion-related acute lung injury: a clinical review. Lancet. 2013;382(9896):984–994.
4. Middelburg RA, van der Bom JG. Transfusion-related acute lung injury not a two-hit, but a multicausal model. Transfusion. 2015;55(5): 953–960.•• Complete description of clinical manifestation of TRALI and transfusion policies to limit TRALI emergence.
5. P.Toy, O.Gajic, P.Bacchetti, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757–1767.
6. R.Kapur, M.Kim, S.Shanmugabhavananthan, et al. C-reactive protein (CRP) enhances murine antibody-mediated transfusion-related acute lung injury (TRALI). Blood. 2015;126(25):2747–2751.
7. P.Toy, P.Bacchetti, B.Grimes, et al. Recipient clinical risk factors predominate in possible transfusion-related acute lung injury. Transfusion. 2015;55(5):947–952.
8. O.Gajic, R.Rana, J.L.Winters, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886–891.
9. A.B.Benson, G.L.Austin, M.Berg, et al. Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med. 2010;36(10):1710–1717.
10. K.Maslanka, M.Uhrynowska, P.Lopacz, et al. Analysis of leucocyte antibodies, cytokines, lysophospholipids and cell microparticles in blood components implicated in post-transfusion reactions with dyspnoea. Vox Sanguinis. 2015;108(1):27–36.
11. H.Odent-Malaure, F.Quainon, P.Ruyer-Dumontier, et al. Transfusion related acute lung injury (TRALI) caused by red blood cell transfusion involving residual plasma anti-HLA antibodies: a report on two cases and general considerations. Clin Dev Immunol. 2005;12(4):243–248.
12. R.F.Xie, P.Hu, W.Li, et al. The effect of platelet-derived microparticles in stored apheresis platelet concentrates on polymorphonuclear leucocyte respiratory burst. Vox Sanguinis. 2014;106(3):234–241.
13. J.P.Tung, J.F.Fraser, M.Nataatmadja, et al. Age of blood and recipient factors determine the severity of transfusion-related acute lung injury (TRALI). Crit Care. 2012;16(1):R19.
14. C.C.Silliman, E.E.Moore, M.R.Kelher, et al. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion. 2011;51(12):2549–2554.
15. R.A.Middelburg, B.A.Borkent-Raven, M.P.Janssen, et al. Storage time of blood products and transfusion-related acute lung injury. Transfusion. 2012;52(3):658–667.• This study shows clearly the impact of the age of platelets on TRALI incidence.
16. C.C.Silliman. The two-event model of transfusion-related acute lung injury. Crit Care Med. 2006;34(5 Suppl):S124–131.•• This review gives us a complete description of TRALI mechanism.
17. C.M.Doerschuk. Mechanisms of leukocyte sequestration in inflamed lungs. Microcirculation. 2001;8(2):71–88.
18. T.M.Carlos, J.M.Harlan. Leukocyte-endothelial adhesion molecules. Blood. 1994;84(7):2068–2101.
19. P.Piccardoni, R.Sideri, S.Manarini, et al. Platelet/polymorphonuclear leukocyte adhesion: a new role for SRC kinases in Mac-1 adhesive function triggered by P-selectin. Blood. 2001;98(1):108–116.
20. K.L.Moore, K.D.Patel, R.E.Bruehl, et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol. 1995;128(4):661–671.
21. K.L.Moore. Structure and function of P-selectin glycoprotein ligand-1. Leuk Lymphoma. 1998;29(1–2):1–15.
22. M.C.Muller, D.Van Stein, J.M.Binnekade, et al. Low-risk transfusion-related acute lung injury donor strategies and the impact on the onset of transfusion-related acute lung injury: a meta-analysis. Transfusion. 2015;55(1):164–175.
23. M.R.Looney, J.X.Nguyen, Y.Hu, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119(11):3450–3461.•• This study elaborates a good mouse model of TRALI to determine the platelet implication in TRALI mechanism.
24. A.Caudrillier, K.Kessenbrock, B.M.Gilliss, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122(7):2661–2671.
25. B.H.Shaz, S.R.Stowell, C.D.Hillyer. Transfusion-related acute lung injury: from bedside to bench and back. Blood. 2011;117(5):1463–1471.
26. R.A.Middelburg, D.Van Stein, E.Briet, et al. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion. 2008;48(10):2167–2176.
27. Y.L.Fung, C.C.Silliman. The role of neutrophils in the pathogenesis of transfusion-related acute lung injury. Transfus Med Rev. 2009;23(4):266–283.
28. B.R.Curtis, J.G.McFarland. Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies. Crit Care Med. 2006;34(5(Suppl)):S118–123.
29. A.L.Peters, D.Van Stein, A.P.Vlaar. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention. Br J Haematol. 2015;170(5):597–614.
30. J.Bux, U.J.Sachs. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol. 2007;136(6):788–799.
31. L.J.Cosgrove, H.A.Vaughan, J.J.Tjandra, et al. HLA (class I) antigens on platelets are involved in platelet function. Immunol Cell Biol. 1988;66(Pt 1):69–77.
32. A.Bunbury, I.Potolicchio, R.Maitra, et al. Functional analysis of monocyte MHC class II compartments. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2009;23(1):164–171.
33. P.A.Roche, K.Furuta. The ins and outs of MHC class II-mediated antigen processing and presentation. Nature reviews. Immunology. 2015;15(4):203–216.
34. J.Bux. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sanguinis. 2011;100(1):122–128.
35. A.Davoren, B.R.Curtis, I.A.Shulman, et al. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion. 2003;43(5):641–645.
36. E.K.Storch, C.D.Hillyer, B.H.Shaz. Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. Blood. 2014;124(12):1868–1872.
37. C.C.Silliman, R.S.Bercovitz, S.Y.Khan, et al. Antibodies to the HLA-A2 antigen prime neutrophils and serve as the second event in an in vitro model of transfusion-related acute lung injury. Vox Sanguinis. 2014;107(1):76–82.
38. M.R.Kelher, T.Masuno, E.E.Moore, et al. Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood. 2009;113(9):2079–2087.
39. M.R.Looney, X.Su, J.A.Van Ziffle, et al. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest. 2006;116(6):1615–1623.
40. M.Nishimura, S.Hashimoto, M.Takanashi, et al. Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transfus Med. 2007;17(2):129–134.
41. P.M.Kopko, T.G.Paglieroni, M.A.Popovsky, et al. TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs. Transfusion. 2003;43(2):177–184.
42. E.Moritz, A.M.Norcia, J.D.Cardone, et al. Human neutrophil alloantigens systems. Anais Da Academia Brasileira De Ciencias. 2009;81(3):559–569.
43. B.Bayat, Y.Tjahjono, A.Sydykov, et al. Anti-human neutrophil antigen-3a induced transfusion-related acute lung injury in mice by direct disturbance of lung endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33(11):2538–2548.
44. T.Berthold, N.Schubert, S.Muschter, et al. HNA antibody-mediated neutrophil aggregation is dependent on serine protease activity. Vox Sang. 2015;109(4):366–374.
45. C.C.Silliman, L.K.Boshkov, Z.Mehdizadehkashi, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101(2):454–462.
46. K.J.Kao, J.C.Scornik, W.J.Riley, et al. Association between HLA phenotype and HLA concentration in plasma or platelets. Hum Immunol. 1988;21(2):115–124.
47. A.L.Peters, M.E.Van Hezel, N.P.Juffermans, et al. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. Blood Rev. 2015;29(1):51–61.
48. P.Toy, K.M.Hollis-Perry, J.Jun, et al. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion. 2004;44(12):1683–1688.
49. C.C.Silliman, A.J.Bjornsen, T.H.Wyman, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion. 2003;43(5):633–640.
50. M.B.Tamarozzi, S.G.Soares, A.Sa-Nunes, et al. Comparative analysis of the pathological events involved in immune and non-immune TRALI models. Vox Sanguinis. 2012;103(4):309–321.
51. F.Rendu, B.Brohard-Bohn. The platelet release reaction: granules’ constituents, secretion and functions. Platelets. 2001;12(5):261–273.
52. H.Heijnen, P.Van Der Sluijs. Platelet secretory behaviour: as diverse as the granules. or not?. J Thromb Haemost. 2015;13(12):2141–2151.
53. J.W.Semple, J.E.ItalianoJr., J.Freedman. Platelets and the immune continuum. Nature reviews. Immunology. 2011;11(4):264–274.
54. S.Hasegawa, N.Tashiro, T.Matsubara, et al. A comparison of FcepsilonRI-mediated RANTES release from human platelets between allergic patients and healthy individuals. Int Arch Allergy Immunol. 2001;125(Suppl 1):42–47.
55. P.H.Lapchak, A.Ioannou, L.Kannan, et al. Platelet-associated CD40/CD154 mediates remote tissue damage after mesenteric ischemia/reperfusion injury. PLoS One. 2012;7(2):e32260.
56. K.Ghoshal, M.Bhattacharyya. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. ScientificWorld J. 2014;2014:781857.
57. M.R.Yeaman. Platelets: at the nexus of antimicrobial defence. Nature reviews. Microbiology. 2014;12(6):426–437.
58. A.Mantovani, C.Garlanda. Platelet-macrophage partnership in innate immunity and inflammation. Nat Immunol. 2013;14(8):768–770.
59. M.Gawaz, S.Vogel. Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. Blood. 2013;122(15):2550–2554.
60. M.T.Rondina, O.Garraud. Emerging evidence for platelets as immune and inflammatory effector cells. Front Immunol. 2014;5:653, 1–6.
61. G.Stack, E.L.Snyder. Cytokine generation in stored platelet concentrates. Transfusion. 1994;34(1):20–25.
62. F.Cognasse, F.Boussoulade, P.Chavarin, et al. Release of potential immunomodulatory factors during platelet storage. Transfusion. 2006;46(7):1184–1189.• Interesting study that highlights the inflammatory potential of PCs during storage.
63. M.Wadhwa, M.J.Seghatchian, A.Lubenko, et al. Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays. Br J Haematol. 1996;93(1):225–234.
64. A.Shanwell, C.Falker, H.Gulliksson. Storage of platelets in additive solutions: the effects of magnesium and potassium on the release of RANTES, beta-thromboglobulin, platelet factor 4 and interleukin-7, during storage. Vox Sanguinis. 2003;85(3):206–212.
65. T.O.Apelseth, T.A.Hervig, T.Wentzel-Larsen, et al. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion. 2006;46(5):800–810.
66. H.Hamzeh-Cognasse, P.Damien, K.A.Nguyen, et al. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. Transfusion. 2014;54(3):613–625.
67. K.Maslanka, G.Smolenska-Sym, H.Michur, et al. Lysophosphatidylcholines: bioactive lipids generated during storage of blood components. Arch Immunol Ther Exp (Warsz). 2012;60(1):55–60.
68. A.N.Boing, C.M.Hau, A.Sturk, et al. Platelet microparticles contain active caspase 3. Platelets. 2008;19(2):96–103.
69. L.Edvardsen, E.Taaning, B.Dreier, et al. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates. Am J Hematol. 2001;67(3):157–162.
70. M.Fujihara, K.Ikebuchi, S.Wakamoto, et al. Effects of filtration and gamma radiation on the accumulation of RANTES and transforming growth factor-beta1 in apheresis platelet concentrates during storage. Transfusion. 1999;39(5):498–505.
71. S.Y.Khan, M.R.Kelher, J.M.Heal, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455–2462.• A study well elaborated to focus on CD40/CD40L implication in TRALI pathophysiology.
72. J.Sahler, S.Spinelli, R.Phipps, et al. CD40 ligand (CD154) involvement in platelet transfusion reactions. Transfusion Clinique Et Biologique: Journal De La Societe Francaise De Transfusion Sanguine. 2012;19(3):98–103.
73. L.Muylle, M.Joos, E.Wouters, et al. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions Transfusion. 1993;33(3):195–199.
74. J.P.Maloney, D.R.Ambruso, N.F.Voelkel, et al. Platelet vascular endothelial growth factor is a potential mediator of transfusion-related acute lung injury. J Pulmonary Respiratory Med. 2014;4:1–7.
75. A.P.Vlaar, W.Kulik, R.Nieuwland, et al. Accumulation of bioactive lipids during storage of blood products is not cell but plasma derived and temperature dependent. Transfusion. 2011;51(11):2358–2366.
76. C.C.Silliman, M.Kelher, D.R.Ambruso. Bioactive lipids from stored cellular blood components: in vitro method is crucial for proper interpretation. Transfusion. 2012;52(5):1155–1157. author reply 1157-1158
77. K.A.Nguyen, H.Hamzeh-Cognasse, M.Sebban, et al. A computerized prediction model of hazardous inflammatory platelet transfusion outcomes. PLoS One. 2014;9(5):e97082.
78. J.S.Bae. Inhibitory effect of orientin on secretory group IIA phospholipase A. Inflammation. 2015;38(4):1631–1638.
79. M.Leshner, S.Wang, C.Lewis, et al PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. Front Immunol. 2012;3:307.
80. P.Li, L.ML, M.R.Lindberg, et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. The Journal of Experimental Medicine. 2010;207(9):1853–1862.
81. G.Zallen, E.E.Moore, J.L.Johnson, et al. New mechanisms by which secretory phospholipase A2 stimulates neutrophils to provoke the release of cytotoxic agents. Arch Surg. 1998;133(11):1229–1233.
82. D.K.Kim, T.Fukuda, B.T.Thompson, et al. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am J Physiol. 1995;269(1 Pt 1):L109–118.
83. L.H.Boudreau, A.C.Duchez, N.Cloutier, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. 2014;124(14):2173–2183.
84. Y.L.Lee, M.B.King, R.P.Gonzalez, et al. Blood transfusion products contain mitochondrial DNA damage-associated molecular patterns: a potential effector of transfusion-related acute lung injury. J Surg Res. 2014;191(2):286–289.
85. F.Cognasse, C.Aloui, K.Anh Nguyen, et al. Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers. Transfusion. 2016;56(2):497–504.
86. N.Blumberg, S.L.Spinelli, C.W.Francis, et al. The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res. 2009;45(2–3):251–260.
87. F.Cognasse, H.Hamzeh-Cognasse, S.Lafarge, et al. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient’s blood mononuclear cells: an in vitro study. Transfusion. 2009;49(1):91–98.
88. H.Hamzeh-Cognasse, F.Cognasse, S.Palle, et al Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunol. 2008;9:54.
89. H.Hamzeh-Cognasse, P.Damien, K.A.Nguyen, et al. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. Transfusion. 2014;54(3):613–625.
90. C.Aloui, A.Prigent, C.Sut, et al. The signaling role of CD40 ligand in platelet biology and in platelet component transfusion. Int J Mol Sci. 2014;15(12):22342–22364.
91. R.Jin, S.Yu, Z.Song, et al. Soluble CD40 ligand stimulates CD40-dependent activation of the beta2 integrin Mac-1 and protein kinase C zeda (PKCzeta) in neutrophils: implications for neutrophil-platelet interactions and neutrophil oxidative burst. PLoS One. 2013;8(6):e64631.
92. M.Rahman, S.Zhang, M.Chew, et al. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann Surg. 2009;250(5):783–790.
93. J.Kaufman, S.L.Spinelli, E.Schultz, et al. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. Journal of Thrombosis and Haemostasis: JTH. 2007;5(4):788–796.
94. P.R.Tuinman, M.C.Gerards, G.Jongsma, et al. Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. Clin Exp Immunol. 2011;165(2):278–284.
95. L.L.Horstman, Y.S.Ahn. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30(2):111–142.
96. A.P.Bode, S.M.Orton, M.J.Frye, et al. Vesiculation of platelets during in vitro aging. Blood. 1991;77(4):887–895.
97. N.O.Solum. Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler Thromb Vasc Biol. 1999;19(12):2841–2846.
98. L.Daniel, F.Fakhouri, D.Joly, et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int. 2006;69(8):1416–1423.
99. S.C.Lo, C.Y.Hung, D.T.Lin, et al. Involvement of platelet glycoprotein Ib in platelet microparticle mediated neutrophil activation. J Biomed Sci. 2006;13(6):787–796.
100. E.Boilard, P.A.Nigrovic, K.Larabee, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010;327(5965):580–583.
101. A.T.Nurden. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105(Suppl 1):S13–33.
102. R.F.Xie, P.Hu, Z.C.Wang, et al. Platelet-derived microparticles induce polymorphonuclear leukocyte-mediated damage of human pulmonary microvascular endothelial cells. Transfusion. 2015;55(5):1051–1057.
103. K.Zibara, E.Chignier, C.Covacho, et al. Modulation of expression of endothelial intercellular adhesion molecule-1, platelet-endothelial cell adhesion molecule-1, and vascular cell adhesion molecule-1 in aortic arch lesions of apolipoprotein E-deficient compared with wild-type mice. Arterioscler Thromb Vasc Biol. 2000;20(10):2288–2296.
104. O.P.Barry, D.Pratico, J.A.Lawson, et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997;99(9):2118–2127.
105. M.McVey, A.Tabuchi, W.M.Kuebler. Microparticles and acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2012;303(5):L364–381.
106. W.Jy, W.W.Mao, L.Horstman, et al. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis. 1995;21(3):217–231. discussion 231a
107. J.A.Bastarache, R.D.Fremont, J.A.Kropski, et al. Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2009;297(6):L1035–1041.
108. B.Bayat, Y.Tjahjono, H.Berghofer, et al. Choline transporter-like protein-2: new von Willebrand factor-binding partner involved in antibody-mediated neutrophil activation and transfusion-related acute lung injury. Arterioscler Thromb Vasc Biol. 2015;35(7):1616–1622.
109. A.Zarbock, K.Singbartl, K.Ley. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116(12):3211–3219.
110. A.Caudrillier, M.R.Looney. Platelet-neutrophil interactions as a target for prevention and treatment of transfusion-related acute lung injury. Curr Pharm Des. 2012;18(22):3260–3266.•• This study reveals clearly the importance of platelet–neutrophil complex in the TRALI pathogenesis.
111. A.S.Weyrich, G.A.Zimmerman. Platelets in lung biology. Annu Rev Physiol. 2013;75:569–591.
112. R.C.Schneider, W.M.Zapol, A.C.Carvalho. Platelet consumption and sequestration in severe acute respiratory failure. Am Rev Respir Dis. 1980;122(3):445–451.
113. C.Page, S.Pitchford. Neutrophil and platelet complexes and their relevance to neutrophil recruitment and activation. Int Immunopharmacol. 2013;17(4):1176–1184.
114. J.Li, K.Kim, A.Barazia, et al. Platelet-neutrophil interactions under thromboinflammatory conditions. Cellular and Molecular Life Sciences: CMLS. 2015;72(14):2627–2643.
115. R.Ehlers, V.Ustinov, Z.Chen, et al. Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha. The Journal of Experimental Medicine. 2003;198(7):1077–1088.
116. D.I.Simon, Z.Chen, H.Xu, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). The Journal of Experimental Medicine. 2000;192(2):193–204.
117. D.Duerschmied, G.L.Suidan, M.Demers, et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood. 2013;121(6):1008–1015.
118. P.Andre, L.Nannizzi-Alaimo, S.K.Prasad, et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106(8):896–899.
119. K.Kessenbrock, M.Krumbholz, U.Schonermarck, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–625.
120. V.Papayannopoulos, K.D.Metzler, A.Hakkim, et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191(3):677–691.
121. G.T.Brown, T.M.McIntyre. Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles. J Immunol. 2011;186(9):5489–5496.
122. K.S.Prasad, P.Andre, M.He, et al. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A. 2003;100(21):12367–12371.
123. V.Brinkmann, U.Reichard, C.Goosmann, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–1535.
124. S.R.Clark, A.C.Ma, S.A.Tavener, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13(4):463–469.
125. O.Bruserud. Bidirectional crosstalk between platelets and monocytes initiated by Toll-like receptor: an important step in the early defense against fungal infections?. Platelets. 2013;24(2):85–97.
126. F.Semeraro, C.T.Ammollo, J.H.Morrissey, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011;118(7):1952–1961.
127. C.M.Ward, T.J.Tetaz, R.K.Andrews, et al. Binding of the von Willebrand factor A1 domain to histone. Thromb Res. 1997;86(6):469–477.
128. G.M.Thomas, C.Carbo, B.R.Curtis, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood. 2012;119(26):6335–6343.
129. M.T.Yiming, D.J.Lederer, L.Sun, et al. Platelets enhance endothelial adhesiveness in high tidal volume ventilation. Am J Respir Cell Mol Biol. 2008;39(5):569–575.
130. J.Grommes, J.E.Alard, M.Drechsler, et al. Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit Care Med. 2012;185(6):628–636.
131. S.Tong, H.Wang, T.Zhang, et al. Accumulation of CD62P during storage of apheresis platelet concentrates and the role of CD62P in transfusion-related acute lung injury. Mol Med Rep. 2015;12(5):7777–7781.
132. Y.Guo, A.Mishra, E.Howland, et al. Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1-mediated neutrophilic acute lung inflammation. Blood. 2015;126(19):2220–2229.
133. X.Peng, P.M.Hassoun, S.Sammani, et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med. 2004;169(11):1245–1251.
134. G.Ortiz-Munoz, B.Mallavia, A.Bins, et al. Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice. Blood. 2014;124(17):2625–2634.
135. D.J.Kor, D.S.Talmor, V.M.Banner-Goodspeed, et al. Lung injury prevention with aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open. 2012;2:5.
136. M.H.Worsley, C.J.Sinclair, C.Campanella, et al. Non-cardiogenic pulmonary oedema after transfusion with granulocyte antibody containing blood: treatment with extracorporeal membrane oxygenation. Br J Anaesth. 1991;67(1):116–119.
137. W.Y.Bassuni, M.A.Blajchman, M.A.Al-Moshary. Why implement universal leukoreduction?. Hematol Oncol Stem Cell Ther. 2008;1(2):106–123.
138. F.B.West, C.C.Silliman. Transfusion-related acute lung injury: advances in understanding the role of proinflammatory mediators in its genesis. Expert Rev Hematol. 2013;6(3):265–276.
139. W.H.Dzik, J.K.Anderson, E.M.O’Neill, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion. 2002;42(9):1114–1122.
140. T.R.Watkins, G.D.Rubenfeld, T.R.Martin, et al. Effects of leukoreduced blood on acute lung injury after trauma: a randomized controlled trial. Crit Care Med. 2008;36(5):1493–1499.
141. T.Wagner, A.Vetter, N.Dimovic, et al. Ultrastructural changes and activation differences in platelet concentrates stored in plasma and additive solution. Transfusion. 2002;42(6):719–727.
142. H.W.Reesink, J.Lee, A.Keller, et al. Measures to prevent transfusion-related acute lung injury (TRALI). Vox Sang. 2012;103(3): 231–259.
143. L.Holness, M.A.Knippen, L.Simmons, et al. Fatalities caused by TRALI. Transfus Med Rev. 2004;18(3):184–188.
144. M.A.Popovsky, R.D.Davenport. Transfusion-related acute lung injury: femme fatale?. Transfusion. 2001;41(3):312–315.
145. D.Van Stein, E.A.Beckers, K.Sintnicolaas, et al. Transfusion-related acute lung injury reports in the Netherlands: an observational study. Transfusion. 2010;50(1):213–220.
146. C.E.Chapman, D.Stainsby, H.Jones, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440–452.
147. M.B.Funk, S.Guenay, A.Lohmann, et al Benefit of transfusion-related acute lung injury risk-minimization measures–German haemovigilance data (2006-2010). Vox Sanguinis. 2012;102(4):317–323.
148. M.B.Funk, M.Heiden, P.Volkers, et al. Evaluation of risk minimisation measures for blood components - based on reporting rates of transfusion-transmitted reactions (1997–2013). Transfus Med Hemother. 2015;42(4):240–246.
149. D.J.Triulzi, S.Kleinman, R.M.Kakaiya, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825–1835.
150. H.Nakazawa, H.Ohnishi, H.Okazaki, et al. Impact of fresh-frozen plasma from male-only donors versus mixed-sex donors on postoperative respiratory function in surgical patients: a prospective case-controlled study. Transfusion. 2009;49(11):2434–2441.
151. A.P.Vlaar, J.M.Binnekade, D.Prins, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med. 2010;38(3):771–778.
152. S.E.Wright, C.P.Snowden, S.C.Athey, et al. Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Crit Care Med. 2008;36(6):1796–1802.